ReviewJournal of asthma and allergy2024
Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types.
Reynold Panettieri et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
18 papers cite it
this papertrialcites it